You are here: Industry Insights > Innovative drugs

News List

A Record High! A Review of Blockbuster New Drugs in China in 2024, with the Number of Innovative Drugs Reaching New Heights! Sophia
January 23, 2025
In 2024, China's pharmaceutical field thrived. NMPA approved 220 new drugs, including 46 Class 1 innovative ones with anti-tumor drugs being the most. New anti-tumor drugs offered hope, and the R&D environment will keep improving.
Selection of Commercial Models for Innovative Drugs WND
May 21, 2024
Marketing is the crucial stage in the life cycle of a pharmaceutical product, directly determining the success of its development. Large pharmaceutical companies typically possess a robust sales system, giving them a unique advantage in terms of first-mov
An Overview to 2023 Pharmaceutical Industry by PharmaSources Experts PharmaSources
March 07, 2024
20 Selected Articles by PharmaSources Experts in 2023
The Narrative of Pharmaceuticals Bestowed with Endorsement and Later Reclaimed by Oblivion by the FDA zhulikou431
March 06, 2024
This document endeavors to compile and elucidate data pertaining to instances where the U.S. FDA, in recent years, has rescinded market approval for pharmaceuticals previously sanctioned.
Pharma Sources Insight April 2023: Innovative Drugs Going Abroad Pharma Sources Insight
April 18, 2023
A look into the innovative drugs R&D and emerging market.
Summary and Brief Analysis of New Drugs Approved by NMPA in 2021 PharmaSources/zhulikou431
March 29, 2022
With the revision and promulgation of the Drug Administration Law in 2019, Chinese drug review and approval system has been strengthened and improved.
Similarities and Differences of Medical Insurance System Development among Foreign Countries and China PharmaSources/Big Cat of Medical Field
January 04, 2022
Recently, the news of national medical insurance negotiations has constantly touched the heartstrings of pharmaceutical people.
Innovative Drugs of Chinese Pharmaceutical Companies have Obtained Overseas Authorization and Developed Rapidly PharmaSources/Xiaoyaowan
December 17, 2021
In March 2007, Chipscreen licensed the global development rights of chidamide, a product under research, to HUYA of the United States at a price of USD 28 million.
ADC vs PDC-- Status Quo of the R&D of ADC-PDC Drug in China and the World PharmaSources/zhulikou431
November 15, 2021
With the sustained investment in China's pharmaceutical industry and the growing attraction of China's pharmaceutical market to global innovative drugs, more projects of innovative drugs have added the listing in China as a necessary part.
Analysis on the Layout of Innovative Drugs in China and Globally PharmaSources/Zhulikou431
October 27, 2021
Recently, there is a saying in the pharmaceutical industry: not all innovative drugs have a future. This saying reminds me of the lyrics - wild lilies also have spring.

Previous page 1 2 Next page